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Role of Genotoxic and Nongenotoxic
Effects in Multistage Carcinogenicity of
Aromatic Amines
by Hans-Gunter Neumann,* Roland Hammerl,*
Wolfgang Hillesheim,* and Michael Wildschutte*
It has been demonstrated in several model systems that tumors arise in a multistage process. Carcin-
ogenic aromatic amines are complete carcinogens, which usually produce tumors in typical target tissues
without anyadditionaltreatment. Thetissuespecificity, however, cannotreadilybeexplainedby genotoxic
effects, and the role of secondary effects is not well understood. Promotional pressure on initiated cells
can be produced by endogenous factors but also by the chemical itself. Comparison of the effects on rat
liver of 2-acetylaminofluorene (AAF) and trans4-acetylaminostilbene (AAS) provides some evidence that
initiating and promoting properties of these chemicals can be separated. AAS is a strong initiator in rat
liver but seems to lack promoting activity; AAF is a less efficient initiator but has tumor promoting
properties. The results obtained so far indicate that promoting pressure is not produced by the acute,
cytotoxic effects of AAF. It is therefore concluded that nongenotoxic, possibly receptor-mediated effects
are involved.
Introduction
Many aromatic amines are complete carcinogens and
produce tumors in typical target tissues. Tissue speci-
ficity and the latency period cannot be correlated well
with genotoxic effects as measured by DNA binding
and the generation of particular adducts (1). For in-
stance, trans-4-acetylaminostilbene (AAS) generates
more DNA adducts in the liver than in any other tissue
of rats but produces liver tumors only when additional
promotional pressure isapplied (2). Bydefinition, there-
fore, this chemical is a tumor initiator in rat liver. 2-
Acetylaminofluorene (AAF), on the other hand, is able
to produce liver tumors without additional promotion,
despite the fact that it binds less efficiently to DNA
than does AAS and is less mutagenic in many in vitro
test systems. It is therefore unlikely that a particularly
strong initial genotoxic effect starts the whole process
of tumor formation in this case. Repair is also not an
adequate explanation for the differences because both
chemicals produce persistent DNA adducts (3). We
therefore assume that AAF, in contrast to AAS, has
some additional properties that create promotional
pressure. We have previously collected data that sup-
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port this working hypothesis (4) by comparing the ef-
fects of these chemicals in the rat liver system at the
biochemical and the biological level, and we now sum-
marize some more recent results.
DNA Adducts In Vivo
DNA adducts ofAAF are well characterized (5), and
there is evidence that N-(deoxyguanosine-8-yl)-2-ami-
nofluorene accumulates after repeated uptake and rep-
resents a promutagenic lesion. With AAS the situation
is much more complicated. The reaction ofN-acetoxy-
AAS, a model ofthe ultimate reactive form, with guan-
ine yields a whole series ofadducts, some ofwhich have
been identified (6). Particularly interesting are two
types ofcyclic adducts that are formed by the addition
ofthe stilbene double bond to either Ni and N2 or N2
and N3 ofguanine. Preliminary findings indicating that
the latter form (called B adducts in previous reports) is
also formed in vivo have now been confirmed. The four
isomers are clearly present in RNA and DNA. The ma-
jor adduct in RNA has not yet been identified. This
major adduct accounts for up to 30% ofradioactive ma-
terial and contains the acetylgroupofAAS. This adduct
is present in DNA only in small amounts. The most
difficult problem in analyzing DNA adducts is the vast
amount (up to 70%) ofnonhydrolyzable material eluting
early from Sephadex LH20 columns. Neither by addi-
tional enzymatic treatment nor by chemical hydrolysisNEUMANN ET AL.
underdepurinatingconditions wasitpossibletodegrade
this material further. Whetherthisis due to intrastrand
or interstrand crosslinks (7) remains to be demon-
strated. AAS is certainly strongly genotoxic, and it is
assumed that its genotoxicity is a result of adduct for-
mation.
AAS As an Initiator in Rats
AAS is a complete carcinogen for rats and produces
tumors quite selectively in Zymbal glands (8). DNA
binding has been demonstrated in many tissues (9),
reaching the highest levels in liver and kidney. The
DNA adducts formed in these tissues must be able to
produce critical lesions and thus initiated cells because
promotional pressure with appropriate secondary treat-
ments results in tumor formation (Table 1).
AAF and AAS As Initiators in Rat
Liver
According to the classical concept, a synergism of
carcinogens should be restricted to chemicals with a
common target tissue. Thus, 4-dimethylaminoazoben-
zene and diethylnitrosamine, two liver carcinogens, act
synergistically (12), but trans-4-dimethylaminostilbene
and diethylnitrosamine, inwhich one ofthe constituents
is known to produce earduct tumors and the other liver
tumors (13), do not act synergistically. In light of the
fact that AAS initiates rat liver cells, the synergism
concept has to be reevaluated by concentrating on the
more refined question ofwhether DNA lesions induced
by different chemicals may be additive and result in a
respective level ofinitiation. This was shown to be the
case with AAS and AAF (14). In addition, AAF turned
out to be a significantly weaker initiator than AAS; a
finding that is supported by the experiments described
below.
AAF As a Promoter
The most surprising result ofthe initiation-promotion
experiments (Fig. 1A) was that the sequence ofadmin-
istration during initiation influenced the results. AAF
and AAS were administered sequentially to adult rats
within 4 weeks. This initiation phase was followed by
partial hepatectomy and phenobarbital in the drinking
water as a promoting regime. When AAS was admin-
Table 1. Role of secondary treatment for the generation of
tumors following initiation with AAS in female Wistar rats.
Secondary treatment Tumor Reference
None Zymbal gland
Zymbalectomy Sebaceous glands in lips (10)
and eye lids
Partial hepatectomy Liver (2)
Phenobarbital Liver
Unilateral nephrectomy Kidney (11)
Cyclodextrin Kidney
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FIGURE 1. Protocol for initiation-promotion experiments in rat
liver. (A) Administration of initiators 2 x 4 doses by gavage to
adult animals. P.H., partial hepatectomy. Phenobarbital, 250 ppm
in the drinking water. (B) Oral administration of initiators 2 x 2
doses in condensed milk to newborn animals. Phenobarbital, 500
ppm in the drinking water. The AAF/AAS group received the
same total dose ofAAS and AAF as in the AAS-AAF group, but
as a mixture.
istered first and AAF second, preneoplastic lesions
grew faster and became larger than when the com-
pounds were applied in the reverse order, despite the
identical promoting treatment. This can hardly be ex-
plained by the lower genotoxic effects of AAF and ap-
pears to be typical of the promoting effects of AAF on
AAS-initiated cells.
Promoting effects of AAF were frequently used in
the initiation-selection protocols of Farber and his as-
sociates (15). Promotion was attributed to growth in-
hibitory, cytotoxic effects of AAF on the surrounding
normal cells, which are thought to be damaged to a
greater degree than preneoplastic cells with their im-
proved capacity to inactivate xenobiotics (16,17).
We began to study the cytotoxic properties of AAF
in isolated perfused rat liver as well as in intact animals
with bile fistulas, but so far we have not been able to
find any adequate biochemical indicators for cytotoxic-
ity. Some ofthe parameters measured are summarized
in Table 2. The following quantitative considerations
support the view that acute toxic effects are not likely
to be involved in liver tumor production by AAF. The
dose rate ofAAF can be estimated to be about 2 nmole/
min x g liver with 0.02% AAF in the diet, which cor-
responds to a dose of about 0.05 mmole/kg x d. In
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Table 2. Indicators for acute toxicity measured in livers of rats
with bile fistula (in vivo) dosed with up to 1 mmole/kg AAF,
or in isolated perfused livers with concentrations up to
50 ,uM AAF.
Effecta
Parameter In vivo Isolated perfused liver
Enzyme leakage
GPT in serum +
LDH in perfusate +
Liver GSH 55%
Oxidative stress
GSSG in bile + +
Redox state
Lactate/pyruvate +
Lipid peroxidation
Thiobarbiturate positive + +
a(±) Indicates no effect; not significantly elevated.
isolated perfused liver, the maximum concentration of
AAF was limited to 50 ,uM due to its low solubility.
This amounts to a dose rate of200 nmole/min x gliver,
which is about 100 times more than during tumor pro-
duction. With intact animals, doses up to 1 nmole/kg
were injected IP, corresponding to a dose rate ofabout
20 nmole/min x g liver, which is still about 10 times as
much as during tumor generation. We therefore con-
clude that AAF has promoting properties that are not
related to the formation of reactive metabolites or re-
active oxygen and may be nongenotoxic in nature (18).
Synergism of AAF and AAS
The question of synergism in a multistage process is
difficult to answer. Early markers such as y-glutamyl-
transpeptidase (GGT)-positive foci in the initiation-pro-
motion experiments mentioned above (14) after 14 and
27 weeks ofpromotion demonstrated effects that were
clearly stronger than expected from adding the effects
produced by the same dose of each compound admin-
istered alone during the same period as in the combi-
nationgroups. Thiswasinterpreted asindicating amore
thanadditive initiatingeffect ofthe combinations. How-
ever, one could argue that the lapse of time between
the last administration ofthe initiatorandthebeginning
of the promoting regime could also influence the out-
come. Inthe newexperiments, therefore, different con-
trol groups were used. Two series ofthe same initiator
were given and compared with both sequences of the
combination of one series of each initiator (Fig. 1A).
The effects were measured after 13 and 26 weeks of
promotion using the expression ofplacental glutathione
transferase (GST-P), GGT, and morphologically dis-
cernible foci in hematoxylin-eosin-stained sections as
markers (Fig. 2). The number of foci per square cen-
timeter, the average size offoci (mm2), and the area of
foci in o/oo of the total area screened were calculated.
The different markers yielded slightly different results.
WithGST-P, smallerfocicouldbeclearlyidentified, and
thus the number of foci is greater than with the other
markers. Morphological alterations represent more ad-
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M GST-P JGGT _ H.E.
FIGURE 2. Comparison of the number (A), average size (B), and
total area (C) of foci in rat liver after oral administration of the
initiator combination indicated to adult animals after partial hep-
atectomy and 26 weeks ofphenobarbital treatment.
vanced stages, sothat the average size offociis greater
in stained sections. These differences are partly com-
pensated when looking at the total area. One overall
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Table 3. Generation of enzyme-altered liver foci in newborn male Wistar rats.a
Total area, per thousand
Initiation day Promotion, mg/L y-GT GST-P
Dose, in drinking water
6, 8 12, 14 [tmole/kg 500 mg/L Week 10 Week 20 Week 10 Week 20
Control pBP 0.04 0.06 0.06 0.3
AAS AAS 100 100 PB 4.2 4.6 6.1 6.0
AAS AAF 100 250 PB 0.5 2.3 0.7 3.4
AAS + AAF AAS + AAF 100/250 100/250 PB 0.8 3.0 1.3 3.4
AAF AAF 250 250 PB 0.4 1.3 0.7 1.6
aPB, phenobarbital
result is that a 5-fold total dose of AAF produces a
smaller effect than AAS, and this seems to be due pri-
marily to the greater number offoci produced by AAS.
In the combination groups, the number offoci seems
to be determined by the second combination partner,
i.e., the figures for AAS-AAF are similar to those of
AAF-AAF, and the figures ofAAF-AAS are similar to
those of AAS-AAS (Fig. 2). The average size is not
significantly different in the two control groups, but
clearly differs betweenthe two combination groups, foci
inthe AAS-AAF group being significantly larger. Ifthe
total area covered by foci is taken as the overall effect,
then the combination AAS-AAF is more efficient than
expected from the addition ofhalfthe effects in the two
controls.
Synergism in a Simplified Initiation-
Promotion Protocol
The use of newborn animals (Fig. 1B) (Table 3) had
several advantages. Partial hepatectomy could be
avoided because the livers are subject to anendogenous
proliferation stimulus during the first 3 weeks of life.
In addition, only two doses of each initiator were re-
quired, which comes closer to single-dose application.
In this experiment AAS was again a better initiator
than AAF. The initiating effects of the two chemicals,
however, were simply additive. Promoting properties
of AAF during initiation were not apparent. The sim-
plified initiation-promotion model using newborn ani-
mals, therefore, appears to be particularly suitable for
testing synergism of initiators. An additional problem
was addressed: Is there a difference ifthe initiators are
administered as a mixture rather than sequentially?
This does not seem to be the case (Table 3).
Conclusions
The results further support the following notions:
AAS is a strong initiator in rat liver. AAF has both
initiating and promoting properties. The initiating ef-
fects ofthese two chemicals generating different types
ofDNA adducts are, at least, additive. Promoting, pre-
sumably nongenotoxic effects, rather than initiating ef-
fects, determine the tumor development in tissues
hitherto called target tissues and the rate of tumor
growth.
Synergistic effects of genotoxic chemicals may be
more important in the real-life situation than hitherto
accepted. In addition, carcinogenicity testingin animals
does notsufficientlyrevealtheroleofsecondary effects.
This adds to the problems encountered in quantitative
risk assessment for humans.
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